Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Deal Watch: Endo Hopes To Boost Generics Unit With Buy-Out Of Par

Executive Summary

J&J is teaming with Achillion to produce a combo regimen for hepatitis C that might compete with offerings from Gilead, AbbVie and Merck. Amgen is dropping out of its collaboration on brodalumab with AstraZeneca due to concerns about suicidality in clinical trials.

You may also be interested in...



Deal Watch: AZ Ups mRNA Stake, Gilead's HIV Innovation, Hospira Returns Lucentis Biosimilar, Pfizer/Takeda End Distribution Deal

Deal activity over the past week saw AstraZeneca stealthily increase its commitment to mRNA player Moderna, Gilead seek innovation in HIV through an alliance with Genmab for its bispecific antibody technology, and Hospira back out of a licensing deal for Pfenex's Lucentis biosimilar, and more.

Novo Nordisk Exits Inflammation R&D To Focus More On Diabetes, Obesity

Danish insulin maker’s decision triggered by failure of its most advanced compound, anti-IL-20, for the treatment of rheumatoid arthritis.

Oncology Is Next Destination For Innate’s Checkpoint Inhibitor After Return From Novo

French biotech Innate Pharma is set to take the anti-NKG2A antibody IPH2201 into Phase II after buying out rights from Novo Nordisk for €2 million up front.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

PS056897

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel